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San Francisco, Calif; Aurora, Colo; and Baltimore, MdABSTRACT
Objective: Antegrade femoral artery access is often used for ipsilateral infrainguinal peripheral vascular intervention.
However, the use of closure devices (CD) for antegrade access (AA) is still considered outside the instructions for use for
most devices. We hypothesized that CD use for antegrade femoral access would not be associated with an increased
odds of access site complications.
Methods: The Vascular Quality Initiative was queried from 2010 to 2019 for infrainguinal peripheral vascular interventions
performedvia femoral AA. Patientswhohadacutdownormultiple access siteswere excluded. Caseswere then stratiﬁed into
whether a CDwas used or not. Hierarchicalmultivariable logistic regressions controlling for hospital-level variationwere used
toexamine the independentassociationbetweenCDuseandaccess site complications. A sensitivity analysisusing coarsened
exactmatchingwas performed using factors different between treatment groups to reduce imbalance between the groups.
Results: Overall, 11,562 cases were identiﬁed and 5693 (49.2%) used a CD. Patients treated with a CD were less likely to be
white (74.1% vs 75.2%), have coronary artery disease (29.7% vs 33.4%), use aspirin (68.7% vs 72.4%), and have heparin
reversal with protamine (15.5% vs 25.6%; all P < .05). CD patients were more likely to be obese (31.6% vs 27.0%), have an
elective operation (82.6% vs 80.1%), ultrasound-guided access (75.5% vs 60.6%), and a larger access sheath (6.0 6 1.0 F vs
5.5 6 1.0 F; P < .05 for all). CD cases were less likely to develop any access site hematoma (2.55% vs 3.53%; P < .01) or a
hematoma requiring reintervention (0.63% vs 1.26%; P < .01) and had no difference in access site stenosis or occlusion
(0.30% vs 0.22%; P ¼ .47) compared with no CD. On multivariable analysis, CD cases had signiﬁcantly decreased odds of
developing any access site hematoma (odds ratio, 0.75; 95% conﬁdence interval, 0.59-0.95) and a hematoma requiring
intervention (odds ratio, 0.56; 95% conﬁdence interval, 0.38-0.81). A sensitivity analysis after coarsened exact matching
conﬁrmed these ﬁndings.
Conclusions: In this nationally representative sample, CD use for AA was associated with a lower odds of hematoma in
selected patients. Extending the instructions for use indications for CDs to include femoral AA may decrease the inci-
dence of access site complications, patient exposure to reintervention, and costs to the health care system. (J Vasc Surg
2020;-:1-8.)
Keywords: Closure devices; Antegrade access; Femoral access; Access site complicationsAlthough retrograde access (RA) is more commonly
used, lower extremity disease may be safely treated
with ipsilateral femoral artery antegrade access (AA).1,2
AA plays an important role in patients with a narrow or
heavily calciﬁed aortic bifurcation, prior aortoiliac ore Division of Vascular and Endovascular Surgery, University of California,
ranciscoa; the Division of Vascular Surgery and Endovascular Therapy,
rsity of Colorado, Aurorab; and the Division of Vascular Surgery and
vascular Therapy, Johns Hopkins University, Baltimore.c
ted by institutional start-up funds (J.C.I.) with additional student
rch support from the Society for Vascular Surgery Student Research
ship Award and the American Heart Association Student Scholarship
.). The content is solely the responsibility of the authors and does not
ssarily represent the ofﬁcial views of the Society for Vascular Surgery or
ican Heart Association. The funding organizations were not involved
e design and conduct of the study, collection, management, analysis,
interpretation of the data, or preparation, review or approval of the
script.
conﬂict of interest: none.
Downloaded for Anonymous User (n/a) at SAN FRANCISCO VA MEDICA
For personal use only. No other uses without permission. Caortofemoral bypass, aortic stent graft, bilateral kissing
iliac stents with a raised bifurcation, and patients with
tortuous iliofemoral anatomy that makes crossing the
aortic bifurcation challenging.3-5 Although femoral AA
can be more technically difﬁcult than RA, and certainPresented at the Thirty-fourth Annual Meeting of the Western Vascular Society,
Maui, Hawaii, September 28 to October 1, 2019.
Additional material for this article may be found online at www.jvascsurg.org.
Correspondence: James C. Iannuzzi, MD, MPH, Division of Vascular and Endo-
vascular Surgery, Department of Surgery, University of California, 400 Parnas-
sus Ave, A-581, San Francisco, CA 94143 (e-mail: james.iannuzzi@ucsf.edu).
The editors and reviewers of this article have no relevant ﬁnancial relationships to
disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a conﬂict of interest.
0741-5214
Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.
https://doi.org/10.1016/j.jvs.2020.01.052
1
L CENTER from ClinicalKey.com by Elsevier on March 17, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
ARTICLE HIGHLIGHTS
d Type of Research: Retrospective analysis of prospec-
tively collected registry data from the Vascular Qual-
ity Initiative
d Key Findings: Closure device (CD) use for antegrade
femoral artery access in 5693 infrainguinal peripheral
vascular interventions was independently associated
with a decreased odds for developing any access site
hematoma (odds ratio, 0.75) or a hematoma
requiring intervention (odds ratio, 0.56), and was
not associated with access site stenosis or occlusion
compared with no CD.
d Take Home Message: The use of CDs for antegrade
femoral artery access is safe, efﬁcacious, and associ-
ated with a decreased odds of access site
hematoma.
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--- 2020patient factors such as obesity may preclude the use of
AA, AA has been reported to have a similar incidence
of access site complications compared with RA.6,7
Arterial access closure devices (CD) allow for expedient
closure, avoidance of prolonged manual compression,
decreased operating room or angiosuite use, and
improved patient satisfaction after peripheral vascular
intervention (PVI).8 However, the instructions for use
(IFU) for most CDs indicate their use only for femoral RA.
An abundance of data exists supporting the use of CDs
for femoral artery access; however, these studies do not
differentiate between patients with RA vs AA.8,9 Although
prima facie it seems unlikely that CDs would function
differently whether access was retrograde or antegrade,
this ﬁnding has yet to be described in a large cohort.
The objective of this study was to examine the associa-
tion of CD use in femoral AA with access site complica-
tions, including hematoma, stenosis, or occlusion. We
hypothesized that CD use would demonstrate no differ-
ence in the incidence of access site complications
compared with no CD use.
METHODS
Prospectively collected data from the 2010 to 2019 So-
ciety for Vascular Surgery Vascular Quality Initiative
(VQI) infrainguinal PVIs database was retrospectively
analyzed. The VQI has been previously described in the
literature.10 Brieﬂy, the VQI is a national quality improve-
ment database that collects patient-level data on
commonly performed vascular procedures, including
in-hospital and long-term outcomes. Data are entered
by participating hospitals and are available to partici-
pating institutions after submission and approval of a
written data request. All variables used in this study
had a missingness of less than 10%. Missing data were
grouped with the referent group to create a conservative
estimate for all independent variables. These data were
deidentiﬁed and did not include any protected health in-
formation, which is therefore not considered human
research, is exempt from institutional review board
approval, and does not require informed consent.
All patients undergoing an infrainguinal PVI with femoral
AA were included (Fig). Patients who had a femoral artery
cutdown, upper extremity access, or access site other than
the femoral artery were excluded. Patients with multiple
access sites (ie, bilateral femoral or femoral and upper
extremity) were excluded as well, owing to the inability
to determine the location of the access site complication.
The primary outcomes were periprocedural access site
complications, which included the development of an
access site hematoma or access site stenosis or occlusion
as deﬁned in the VQI. The secondary outcome was peri-
procedural development of an access site hematoma
requiring an intervention, which was deﬁned as transfu-
sion to treat associated blood loss, thrombin injection,
or surgical repair.Downloaded for Anonymous User (n/a) at SAN FRANCISCO VA MED
For personal use only. No other uses without permissioDemographic variables examined included age, sex,
white race, preoperative ambulatory status (independent
or with assistance), Medicare/Medicaid as primary
insurer, obesity (body mass index $30 kg/m2), current
smoking status, coronary artery disease (CAD), hyperten-
sion, diabetes mellitus, congestive heart failure, chronic
obstructive pulmonary disease, or dialysis (functioning
renal transplant or on hemodialysis or peritoneal dialysis),
and preoperative medications (angiotensin-converting
enzyme inhibitor, aspirin, statin, P2Y12 inhibitors, and
anticoagulant [warfarin, direct thrombin inhibitors, or
factor Xa inhibitors]). Prior operative history included his-
tory of coronary artery bypass graft (CABG), percutaneous
coronary intervention (PCI), carotid endarterectomy, ca-
rotid artery stent, major amputation (below knee or prox-
imal amputation), inﬂow stent, angioplasty, or bypass,
and infrainguinal stent, angioplasty, or bypass. Proce-
dural details that were examined included elective oper-
ation, indication for procedure, right-sided access,
ultrasound-guided access, largest sheath used, amount
of contrast, and heparin reversal with protamine.
There were a total of seven unique CDs registered in
this cohort: Perclose (Abbott, Santa Clara, Calif), Starclose
(Abbott), Mynx (Cardinal Health, Dublin, Ohio), Angioseal
(Terumo, Somerset, NJ), Femoral Introducer Sheath &
Hemostasis (Morris Innovative, Bloomington, Ind), Exo-
Seal Vascular Closure System (Cordis, Santa Clara, Calif),
TR Band (Terumo), and other. Consistent with the VQI
Society for Vascular Surgery Device Identiﬁcation Policy,
the identities of the individual CDs were blinded, and
analysis was constrained to CDs as a whole.
Statistical analysis. All statistical analyses were per-
formed using STATA version 15.0 (StataCorp, College Sta-
tion, Tex). Cases were then stratiﬁed into whether a CD
was used or not. Summary statistics were reported using
mean and standard deviation for continuous variables,ICAL CENTER from ClinicalKey.com by Elsevier on March 17, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Fig. Cohort inclusion criteria. PVI, Peripheral vascular intervention; SVS, Society for Vascular Surgery; VQI, Vascular
Quality Initiative.
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Volume -, Number -along with frequency and percentage for categorical var-
iables. Between group differences were calculated using
a c2 test for categorical variables and a two-tailed Stu-
dent t-test for continuous variables. Hierarchical multi-
variable logistic regressions controlling for hospital-level
variation were used to examine the independent asso-
ciation between CD use and access site complications.
Variables returning a P value of less than .10 on univariate
analyses progressed to inclusion in the multivariable
models. The models were constructed in a stepwise
manual method using a P value of less than .05 for
retention in the models.
To decrease imbalance and bias associated with obser-
vational data, the two groups (CD and no CD) were then
matched on aspirin use and baseline demographics,
comorbidities, operative history, and procedural details
that differed on baseline analyses (P < .05) using coars-
ened exact matching (CEM).11 In brief, CEM organizes var-
iables to discrete values using a binning strategy. Each
participant is then assigned a bin signature, which is
used to match between groups. CEM reduces imbal-
ance, model dependence, estimation error, researcher
bias, and variance between groups. This decrease in
imbalance is denoted by the L1 statistic; imbalance de-
creases as the L1 statistic declines. Sensitivity analyses
then assessed the association between CDs and the out-
comes of interest after CEM.
RESULTS
Overall, 164,532 cases of infrainguinal PVI were identi-
ﬁed and 11,562 patients (7.0%) had isolated percutaneous
AA (Fig). Of these, a CD was used in 5693 cases (49.2%)
(Table I). Patients treated with a CD were less likely to
be white (74.1% vs 75.2%), have CAD (29.7% vs 33.4%),Downloaded for Anonymous User (n/a) at SAN FRANCISCO VA MEDICA
For personal use only. No other uses without permission. Cuse aspirin (68.7% vs 72.4%), and have heparin reversal
with protamine (15.5% vs 25.6%; all P < .05). CD use was
associated with obesity (31.6% vs 27.0%), elective opera-
tions (82.6% vs 80.1%), ultrasound-guided access (75.5%
vs 60.6%), and a larger access sheath (6.0 6 1.0 F vs
5.5 6 1.0 F; P < .05 for all; Table II).
CD cases were less likely to develop an access site hema-
toma (2.55% vs 3.53%; P ¼ .002) or a hematoma requiring
reintervention (0.63% vs 1.26%; P ¼ .001) and had no differ-
ence in access site stenosis or occlusion (0.30% vs 0.22%;
P ¼ .467) compared with no CD (Table III). On multivari-
able adjusted analysis, patients treated with a CD had
signiﬁcantly decreased odds of developing any access
site hematoma (odds ratio [OR], 0.75; 95% conﬁdence in-
terval [CI], 0.59-0.95; Table IV) and a hematoma requiring
intervention (OR, 0.56; 95% CI, 0.38-0.81; Table V). Consis-
tent with baseline analyses, there was no signiﬁcant asso-
ciation between CD and access site stenosis or occlusion
on multivariable analysis (Table VI).
Using CEM, the groups were then matched on white
race, obesity, CAD, congestive heart failure, aspirin use,
elective status, ultrasound guidance, largest sheath size
used, heparin reversal with protamine, and prior CABG
or PCI, major amputation, inﬂow stent, angioplasty, or
bypass, and infrainguinal stent, angioplasty, or bypass.
Prematching imbalance of L1 ¼ 0.65 decreased post-
match to an imbalance of L2 ¼ 0.03, which indicated a
decreased imbalance between the groups. After CEM,
5975 total cases were included, and a CD was used in
3273 cases (Supplementary Tables I and II, online only).
Although differences between groups were still appreci-
ated among some variables, the degree of differences
were smaller than before CEM. Sensitivity analyses after
CEM conﬁrmed associations between CD use and anyL CENTER from ClinicalKey.com by Elsevier on March 17, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
Table I. Baseline characteristics
Characteristics CD (n ¼ 5693) No CD (n ¼ 5869) P valuea
Demographics
Age, years .077
<60 1146 (20.1) 1090 (18.6)
60-69 1539 (27.0) 1554 (26.5)
70-79 1635 (28.7) 1724 (29.4)
$80 1373 (24.1) 1501 (25.6)
Female sex 1866 (32.8) 1984 (33.8) .244
White 4221 (74.1) 4683 (79.8) <.001
Ambulatory 4220 (74.1) 4441 (75.2) .207
Medicare/Medicaid 3577 (67.9) 3429 (66.4) .128
Comorbidities
Obese 1799 (31.6) 1586 (27.0) <.001
Current smoker 1425 (25.0) 1382 (23.6) .065
CAD 1690 (29.7) 1958 (33.4) <.001
Prior CABG or PCI 1868 (32.8) 2082 (35.5) .003
Prior CEA or CAS 157 (2.8) 147 (2.5) .416
Hypertension 4981 (87.5) 5190 (88.4) .123
Diabetes 3330 (58.5) 3385 (57.7) .376
Congestive heart failure 1226 (21.5) 1398 (23.8) .003
COPD 1205 (21.2) 1228 (20.9) .749
Dialysis 754 (13.2) 828 (14.0) .233
Preoperative medications
ACE inhibitor 2573 (45.2) 2466 (42.0) .001
Aspirin 3908 (68.7) 4251 (72.4) <.001
Anticoagulant 97 (1.7) 94 (1.6) .715
P2Y12 inhibitor 2432 (42.7) 2438 (41.5) .200
Statin 3789 (66.6) 4044 (68.9) .007
ACE, Angiotensin-converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAS, carotid artery stent; CD, closure device;
CEA, carotid endarterectomy, COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention.
Values are number (%). Boldface entries indicate statistical signiﬁcance.
aCalculated using a c2 test for categorical variables and a Student t-test for continuous variables.
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--- 2020access site hematoma (OR, 0.74; 95% CI, 0.54-1.00) and
access site hematoma requiring intervention (OR, 0.54;
95% CI, 0.29-0.99; Table VII).
DISCUSSION
In this nationally representative surgical quality
improvement database, CD use for femoral AA was asso-
ciated with lower odds of any access site hematoma and
hematoma requiring intervention when compared with
no CD use. Although the overall incidence of access
site stenosis or occlusion was generally low (0.26%), the
use of a CD was not associated with an increased odds
for stenosis or occlusion. These results collectively sug-
gest that CDs may be safely used for femoral AA and
may improve access site outcomes and the incidence
of complications in selected cases.
On baseline analyses, patients who were treated with a
CD had a higher proportion of obesity, which has previ-
ously been reported to independently predict access siteDownloaded for Anonymous User (n/a) at SAN FRANCISCO VA MED
For personal use only. No other uses without permissiocomplications in patients undergoing antegrade PVI,
even when a CD was used.12 The burden of overall athero-
sclerotic disease was lower in the CD group compared
with the no CD group, as indicated by a lower proportion
of patients with a history of CAD, CABG, PCI, major ampu-
tation, and previous inﬂow or infrainguinal stent, angio-
plasty, or bypass. Patients receiving an intervention
owing to occlusive disease were also less likely to be
treatedwith aCD. This ﬁnding likely represents a hesitancy
to use a CD in atherosclerotic or stenosed vessels, because
deployment is anecdotally more challenging. Reports
suggest that CDs have similar efﬁcacy and rates of compli-
cations in patients with peripheral artery disease or calci-
ﬁed plaque.13-16 CDs had a lower proportion of patients
treated with aspirin, which may be protective against
postoperative hematoma, but they also had a 10% lower
rate of heparin reversal with protamine.
Patients treated with a CD had a larger mean sheath
size, which has been reported to be independentlyICAL CENTER from ClinicalKey.com by Elsevier on March 17, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Table II. Procedural details
Characteristics CD (n ¼ 5693) No CD (n ¼ 5869) P valuea
Operative history
Prior major amputation (ipsilateral or contralateral) 870 (15.3) 1118 (19.1) <.001
Prior inﬂow stent or angioplasty <.001
None 4989 (87.6) 4990 (85.0)
Ipsilateral 222 (3.9) 247 (4.2)
Contralateral 177 (3.1) 216 (3.7)
Bilateral 305 (5.4) 416 (7.1)
Prior inﬂow bypass <.001
None 5429 (95.4) 5483 (93.4)
Ipsilateral 74 (1.3) 81 (1.4)
Contralateral 52 (0.9) 58 (1.0)
Bilateral 138 (2.4) 247 (4.2)
Prior infrainguinal stent or angioplasty .001
None 3436 (60.4) 3338 (56.9)
Ipsilateral 1067 (18.7) 1237 (21.1)
Contralateral 657 (11.5) 698 (11.9)
Bilateral 533 (9.4) 596 (10.2)
Prior infrainguinal bypass <.001
None 5088 (89.4) 4918 (83.8)
Ipsilateral 228 (4.0) 335 (5.7)
Contralateral 284 (5.0) 435 (7.4)
Bilateral 93 (1.6) 181 (3.1)
Procedural details
Elective 4703 (82.6) 4703 (80.1) .001
Indication <.001
Occlusive disease 5105 (89.7) 5509 (93.9)
Aneurysm 231 (4.1) 105 (1.8)
Occlusive or aneurysm 40 (0.7) 24 (0.4)
None/unknown 317 (5.6) 231 (3.9)
Right-sided access 3105 (54.5) 3168 (54.0) .550
Ultrasound guidance 4299 (75.5) 3556 (60.6) <.001
Largest sheath size, F 6.0 6 1.0 5.5 6 1.0 <.001
Contrast, mL 76.6 6 51.4 77.6 6 53.3 .317
Protamine 883 (15.5) 1505 (25.6) <.001
CD, Closure device.
Values are mean 6 standard deviation or number (%). Boldface entries indicate statistical signiﬁcance.
aCalculated using a c2 test for categorical variables and a Student t-test for continuous variables.
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Volume -, Number -associated with access site complications after femoral
RA and AA.17,18 Patients treated with a CD were also
15% more likely to have had ultrasound-guided access,
which has been reported to be protective from access
site complications.19,20 After CEM, differences in baseline
characteristics, including a history of previous inﬂow or
infrainguinal stent, angioplasty, or bypass, indication for
intervention, ultrasound guidance, largest sheath size,
and heparin reversal with protamine were ameliorated
and the results of the multivariable models remained
largely unchanged.Downloaded for Anonymous User (n/a) at SAN FRANCISCO VA MEDICA
For personal use only. No other uses without permission. CCragg et al21 reported in a prospective study of 556 pa-
tients undergoing femoropopliteal angioplasty that
compared with femoral RA, AA did not have a signiﬁ-
cantly higher rate of access site complications (AA, 3.7%
vs RA, 1.1%; P ¼ .186), which were deﬁned as retroperito-
neal hematoma, pseudoaneurysm, hematoma requiring
transfusion, arteriovenous ﬁstula formation, acute throm-
bosis, and need for surgical repair. Although not statisti-
cally signiﬁcant, Cragg et al21 also reported fewer access
site complications in patients treated with CDs.
Siracuse et al7 also reported no difference in access siteL CENTER from ClinicalKey.com by Elsevier on March 17, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
Table III. Access site complications
Access site
complications
CD
(n ¼ 5693)
No CD
(n ¼ 5869) P valuea
Hematoma .004
No 5548 (97.5) 5662 (96.5)
Minor 109 (1.91) 133 (2.27)
Transfusion 20 (0.35) 39 (0.66)
Thrombin injection 3 (0.05) 12 (0.20)
Operative treatment 13 (0.23) 23 (0.39)
Any hematoma 145 (2.55) 207 (3.53) .002
Hematoma requiring
intervention
36 (0.63) 74 (1.26) .001
Access site stenosis
or occlusion
17 (0.30) 13 (0.22) .467
CD, Closure device.
Values are number (%). Boldface entries indicate statistical
signiﬁcance.
aCalculated using a c2 test.
Table IV. Multivariable analysis of any access site
hematoma
Covariates OR 95% CI P value
CD 0.75 0.59-0.95 .018
Age, years: Ref <60
60-69 0.76 0.50-1.14 .180
70-79 1.48 1.06-2.08 .022
>80 1.75 1.24-2.46 .001
Female sex 1.50 1.21-1.86 <.001
Prior inﬂow stent or
angioplasty: Ref none
Ipsilateral 1.68 1.12-2.53 .012
Contralateral 1.17 0.68-2.02 .571
Bilateral 1.35 0.94-1.96 .105
Prior infrainguinal
bypass: Ref none
Ipsilateral 1.47 0.96-2.24 .074
Contralateral 1.64 1.12-2.42 .012
Bilateral 1.02 0.46-2.25 .959
Contrast, mL 1.002 1.000-1.005 .027
Elective 0.75 0.59-0.96 .022
Diabetes 0.70 0.55-0.88 .003
Prior major amputation
(ipsilateral or contralateral)
0.70 0.51-0.96 .027
CD, Closure device; CI, conﬁdence interval; OR, odds ratio.
Boldface entries indicate statistical signiﬁcance.
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--- 2020complications, including hematoma, between femoral
RA and AA, although this study did not report on the
use of CDs.
Owing to the VQI device identiﬁcation policy, the identi-
ties of the individual devices were unable to be deter-
mined in the current study. However, previous reports
support the feasibility and safety of the use of a wide
range of CDs for femoral AA.22 Duda et al23 examined
the use of suture-mediated CDs, Techstar and Prostar
Plus devices (Abbott) in 80 patients undergoing femoro-
popliteal angioplasty and reported an access site hema-
toma rate of 5%.23 Collagen- and polyethylene glycol
plug-mediated CDs have also been reported to perform
adequately in femoral AA. In 2374 diabetic patients with
critical limb ischemia, the use of the Angio-Seal CD for
femoral AA was associated with the lowest rate of major
access-site complications (20/1889 [1.1%]) compared with
RAAngio-Seal use (5/278 [1.8%]) andmanual compression
(4/205 [2.0%]).24 Pruski et al25 reported a 95% (63/66) pro-
cedure success rate and no major access site complica-
tions after using the Mynx CD for femoral AA for PVI.
However, it is important to note that the Angio-Seal de-
vice is the only CD that includes use for AA in the IFU.
The ExoSeal Vascular Closure System is the most stud-
ied CD for femoral AA, although the studies are limited
by small sample sizes. Boschewitz et al26 reported a
98% (145/148) technical success using the ExoSeal, no
major access site complications, and a single occurrence
of an access site hematoma of less than 3 cm (1/148
[0.7%]). However, there was a signiﬁcant association
(P < .05) between preoperative aspirin, clopidogrel, and
abciximab use with requiring additional manual
compression for hemostasis.26 In the current study, no
preoperative medications were associated with access
site hematoma and were therefore not included in the
multivariable models. In two other studies using theDownloaded for Anonymous User (n/a) at SAN FRANCISCO VA MED
For personal use only. No other uses without permissioExoSeal CD for femoral AA, rates of postoperative hema-
toma were 3.4% (2/59) and 5.4% (9/168).27,28 Similar to the
previously mentioned studies, the use of the Starclose
CD has also been reported to be safe and efﬁcacious in
femoral AA, which was demonstrated in 30 patients
with critical limb ischemia who underwent peripheral
angioplasty.29
The data reported in this study suggest that CDs
decrease hematoma formation without increasing vessel
stenosis when deployed for femoral AA closure, which is
consistent with the results reported in other studies.
However, this is the largest andmost nationally represen-
tative sample size studied to date. Using CDs for femoral
AA may decrease access site complications and oper-
ating room use.
Limitations. This study has limitations. Although data
in the VQI are collected prospectively, this was a retro-
spective review of a large database. Although the VQI
collects data on the development of access site arterio-
venous ﬁstula and pseudoaneurysms, these variables
were very poorly reported with a missing rate of more
than 60%. This study therefore cannot make any mean-
ingful conclusions on the effect of CDs on access site
arteriovenous ﬁstula or pseudoaneurysm. The VQI
does collect data on failed CD deployment attempts
but the variable had only started to be recorded inICAL CENTER from ClinicalKey.com by Elsevier on March 17, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
Table V. Multivariable analysis of access site hematoma
requiring intervention
Covariates OR 95% CI P value
CD 0.56 0.38-0.81 .002
Age, years: Ref <60
60-69 0.96 0.44-2.08 .918
70-79 2.46 1.31-4.61 .005
>80 2.67 1.36-5.22 .004
Prior infrainguinal
bypass: Ref none
Ipsilateral 1.94 0.96-3.90 .063
Contralateral 1.87 1.04-3.35 .037
Bilateral 2.48 1.11-5.50 .026
Female sex 1.99 1.34-2.97 .001
Congestive heart failure 1.72 1.11-2.68 .016
Elective 0.56 0.35-0.89 .015
CD, Closure device; CI, conﬁdence interval; OR, odds ratio.
Boldface entries indicate statistical signiﬁcance.
Table VI. Multivariable analysis of access site stenosis or
occlusion
Covariates OR 95% CI P value
CD 1.43 0.60-3.39 .414
Prior CABG
or PCI
2.65 1.35-5.21 .005
Elective 0.32 0.14-0.72 .006
CABG, Coronary artery bypass graft; CI, conﬁdence interval; OR, odds
ratio; PCI, percutaneous coronary intervention.
Boldface entries indicate statistical signiﬁcance.
Table VII. Multivariable analysis of access complications
with matched data comparing the use of closure devices
(CD)a
Complication OR 95% CI P value
Any hematomab 0.74 0.54-1.00 .053
Hematoma requiring interventionc 0.54 0.29-0.99 .047
Stenosis or occlusiond 0.97 0.28-3.42 .963
CABG, Coronary artery bypass graft; CI, conﬁdence interval; CHF,
congestive heart failure; OR, odds ratio; PCI, percutaneous coronary
intervention.
Boldface entries indicate statistical signiﬁcance.
aMatched for white race, obesity, coronary artery disease, CHF, aspirin
use, elective procedure, ultrasound guidance, largest sheath size used,
heparin reversal with protamine, and prior CABG or PCI, major
amputation, inﬂow stent or angioplasty, inﬂow bypass, infrainguinal
stent or angioplasty, and infrainguinal bypass.
bAdjusted for age, sex, elective operation, volume of contrast used,
history of diabetes, prior major amputation, prior inﬂow stent or an-
gioplasty, and prior infrainguinal bypass.
cAdjusted for age, sex, elective operation, CHF, and prior infrainguinal
bypass.
dAdjusted for elective operation and history of CABG or PCI.
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Volume -, Number -2015 and is very poorly reported (<50%) in the years that
it was collected and was therefore not included in this
study. Therefore, we cannot accurately determine the
rate of CD deployment failure. However, because pa-
tients with femoral artery cutdowns were excluded
from this study, that would include patients who had
failed CD deployment and required a cutdown to
salvage. Owing to the way the VQI PVI data are orga-
nized, this study did not include patients with multiple
access sites (ie, bilateral femoral or femoral and upper
extremity). Owing to the VQI device identiﬁcation pol-
icy, the identities of the individual CDs were unable to
be determined and analyses were only able to be
completed using an aggregate CD variable. It is possible
that only certain CDs, or that certain forms of CDs (ie,
suture mediated or collagen mediated), may confer a
lesser odds of access site hematoma. Although, owing
to the low incidence of access site complications,
even if CD identities were known, analyses of individual
devices would likely be limited by low power. Further
study of these individual devices will be required before
making formal changes to the IFU.Downloaded for Anonymous User (n/a) at SAN FRANCISCO VA MEDICA
For personal use only. No other uses without permission. CAnalyses of access site stenosis or occlusion are likely
underpowered as the incidence of complication was
low (only 30 total recorded cases). Access site stenosis
or occlusion may also be underreported since it may
not present acutely or be initially symptomatic and
would therefore not be recorded in the VQI. Last,
because the VQI does not collect long-term follow-up
data on access site complications, all of the data pre-
sented in this study represents periprocedural outcomes
and conclusions cannot be made regarding the long-
term impact of CDs.
CONCLUSIONS
In this nationally representative sample, the use of CDs
for AA was associated with a lower odds of postoperative
hematoma and hematoma requiring reintervention. CDs
for AA may improve access site outcomes with a
commensurate increase in patient satisfaction and cost
savings to the health care system.AUTHOR CONTRIBUTIONS
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Supplementary Table I (online only). Baseline charac-
teristics after matching
Characteristics
CD
(n ¼ 3273)
No CD
(n ¼ 2702) P valuea
Demographics
Age, years .543
<60 639 (19.5) 495 (18.3)
60-69 834 (25.5) 699 (25.9)
70-79 926 (28.3) 753 (27.9)
>80 874 (26.7) 755 (27.9)
Female sex 1126 (34.4) 963 (35.6) .318
White 2539 (77.6) 2222 (82.2) <.001
Ambulatory 2540 (77.6) 2158 (79.9) .034
Medicare/Medicaid 2031 (66.5) 1578 (65.5) .424
Comorbidities
Obese 867 (26.5) 650 (24.1) .031
Current smoker 830 (25.4) 649 (24.0) .232
CAD 767 (23.4) 711 (26.3) .010
Prior CABG or PCI 898 (27.4) 809 (29.9) .033
Prior CEA or CAS 85 (2.6) 63 (2.3) .511
Hypertension 2795 (85.4) 2345 (86.8) .122
Diabetes 1855 (56.7) 1468 (54.3) .069
Congestive heart
failure
487 (14.9) 419 (15.5) .501
COPD 584 (17.8) 525 (19.4) .116
Dialysis 379 (11.6) 329 (12.2) .478
Preoperative
medications
ACE inhibitor 1505 (46.0) 1150 (42.6) .008
Aspirin 2327 (71.1) 2022 (74.8) .001
Anticoagulant 44 (1.3) 33 (1.2) .675
P2Y12 inhibitor 1257 (38.4) 986 (36.5) .128
Statin 2083 (63.6) 1769 (65.5) .142
ACE, Angiotensin-converting enzyme; CABG, coronary artery bypass
graft; CAD, coronary artery disease; CAS, carotid artery stent; CEA, ca-
rotid endarterectomy; CD, closure device; COPD, chronic obstructive
pulmonary disease; PCI, percutaneous coronary intervention.
Values are number (%). Boldface entries indicate statistical
signiﬁcance.
aCalculated using a c2 test for categorical variables and a Student’s t-
test for continuous variables.
Supplementary Table II (online only). Procedural details
after matching
Characteristics
CD
(n ¼ 3273)
No CD
(n ¼ 2702)
P
valuea
Operative history
Prior major amputation
(ipsilateral
or contralateral)
258 (7.9) 214 (7.9) .957
Prior inﬂow stent
or angioplasty
.003
None 3158 (96.5) 2564 (94.9)
Ipsilateral 29 (0.9) 21 (0.8)
Contralateral 25 (0.8) 28 (1.0)
Bilateral 61 (1.9) 89 (3.3)
Prior inﬂow bypass .560
None 3244 (99.1) 2668 (98.7)
Ipsilateral 3 (0.1) 3 (0.1)
Contralateral 3 (0.1) 3 (0.1)
Bilateral 23 (0.7) 28 (1.0)
Prior infrainguinal
stent or angioplasty
.769
None 2285 (69.8) 1903 (70.4)
Ipsilateral 552 (16.9) 429 (15.9)
Contralateral 257 (7.9) 220 (8.1)
Bilateral 179 (5.5) 150 (5.6)
Prior infrainguinal
bypass
.892
None 3179 (97.1) 2616 (96.8)
Ipsilateral 44 (1.3) 38 (1.4)
Contralateral 46 (1.4) 44 (1.6)
Bilateral 4 (0.1) 4 (0.2)
Procedural details
Elective 2870 (87.7) 2354 (87.1) .511
Indication .158
Occlusive disease 3021 (92.3) 2527 (93.5)
Aneurysm 63 (1.9) 39 (1.4)
Occlusive or aneurysm 8 (0.2) 10 (0.4)
None/unknown 181 (5.5) 126 (4.7)
Right-sided access 1820 (55.6) 1484 (54.9) .597
Ultrasound guidance 2536 (77.5) 1791 (66.3) <.001
Largest sheath size, F 5.8 6 0.6 5.6 6 0.7 <.001
Contrast, mL 77.0 6 50.9 82.3 6 55.9 <.001
Protamine 389 (11.9) 462 (17.1) <.001
CD, Closure device.
Values are mean 6 standard deviation or number (%). Boldface entries
indicate statistical signiﬁcance.
aCalculated using a c2 test for categorical variables and a Student t-test
for continuous variables.
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